Patents by Inventor Carmine Carpenito

Carmine Carpenito has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IL1RAP ANTIBODIES AND USES THEREOF
    Publication number: 20240392013
    Abstract: The present disclosure provides isolated anti-IL1RAP antibodies comprising the complementarity determining regions (CDRs) amino acid sequences, as disclosed herein. The disclosure further provides specific variable heavy chain and variable light chain amino acid sequences of these isolated anti-IL1RAP antibodies. The anti-IL1RAP antibodies target downstream IL1RAP activity appear useful for treating diseases such as cancer.
    Type: Application
    Filed: September 27, 2022
    Publication date: November 28, 2024
    Applicant: STELEXIS THERAPEUTICS, LLC
    Inventors: Patrick James DOYLE, Zoi KAROULIA, Carmine CARPENITO, Jiahao CHEN, Lumie Marie Josephine BENARD, Adriana Permaul ROOPNARIANE, Yasumi NAKAYAMA, Lynn BIDERMAN, Bozena BUGAJ-GAWEDA, Ilhem GUERNAH, Ivo C. LORENZ, Dana Yen Mei DUEY, John Andrew LIPPINCOTT
  • Anti-CD137 antibodies for combination with anti-PD-L1 antibodies
    Patent number: 12037406
    Abstract: The present invention relates to antibodies that bind to human CD137 and display agonist activity, and may be useful for treating solid and hematological tumors alone and in combination with anti-human PD-L1 antibodies, chemotherapy, and ionizing radiation.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: July 16, 2024
    Assignee: Eli Lilly and Company
    Inventors: Carmine Carpenito, Yiwen Li
  • IL-8 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20230416355
    Abstract: Described herein are anti-IL-8 antibodies, compositions thereof, and methods of use thereof. The anti-IL-8 antibodies N would be useful in methods of inhibiting tumor formation or growth or a combination thereof. Described herein are also methods of using the anti-IL-8 antibodies for methods of treating a disease, wherein diseases may include cancer, a tumor, or a viral infection.
    Type: Application
    Filed: August 5, 2021
    Publication date: December 28, 2023
    Applicant: STELEXIS THERAPEUTICS, LLC
    Inventors: Keren Paz, Nicole Covino, Yasumi Nakayama, Patrick James Doyle, Carmine Carpenito, Lynn Biderman, Bozena Bugaj-Gaweda, John Andrew Lippincott, Dana Yen Mei Duey
  • ANTI-CD137 ANTIBODIES FOR COMBINATION WITH ANTI-PD-L1 ANTIBODIES
    Publication number: 20210054088
    Abstract: The present invention relates to antibodies that bind to human CD137 and display agonist activity, and may be useful for treating solid and hematological tumors alone and in combination with anti-human PD-L1 antibodies, chemotherapy, and ionizing radiation.
    Type: Application
    Filed: March 15, 2019
    Publication date: February 25, 2021
    Inventors: Carmine CARPENITO, Yiwen LI
  • Anti-Tim-3 antibodies
    Patent number: 10253096
    Abstract: The present invention relates to antibodies that bind human T-cell immunoglobulin- and mucin-domain-containing protein-3 (Tim-3), and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: April 9, 2019
    Assignee: Eli Lilly and Company
    Inventors: Yi Zhang, Yang Shen, Carmine Carpenito, Yiwen Li
  • ANTI-TIM-3 ANTIBODIES
    Publication number: 20180057591
    Abstract: The present invention relates to antibodies that bind human T-cell immunoglobulin- and mucin-domain-containing protein-3 (Tim-3), and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and ionizing radiation.
    Type: Application
    Filed: August 17, 2017
    Publication date: March 1, 2018
    Inventors: Yi Zhang, Yang Shen, Carmine Carpenito, Yiwen Li